BTIG Maintains Buy on Vaxcyte, Raises Price Target to $160
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Thomas Shrader has maintained a Buy rating on Vaxcyte (NASDAQ:PCVX) and raised the price target from $98 to $160.
September 03, 2024 | 5:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Thomas Shrader has maintained a Buy rating on Vaxcyte and significantly raised the price target from $98 to $160, indicating strong confidence in the company's future performance.
The increase in the price target from $98 to $160 by BTIG suggests a strong positive outlook for Vaxcyte's stock. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100